Methodology of clinical studies dealing with the treatment of envenomation

Toxicon

Volumn 55, Issue 7, 2010, Pages 1195-1212

  Chippaux, Jean Philippe ^a   Stock, Roberto P ^b   Massougbodji, Achille ^c  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b INSTITUTO DE BIOTECNOLOGÍA   (Mexico)

^c UNIVERSITY OF ABOMEY CALAVI   (Benin)

Author keywords

Clinical studies; Clinical trial; Envenomations; Methodology; Treatment

Indexed keywords

PLACEBO; VENOM ANTISERUM;

BITE; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENVENOMATION; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; METHODOLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; SCORPION; SNAKEBITE; SPIDER BITE; TOXICOLOGY;

ANIMALS; ANTIVENINS; BITES AND STINGS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INSECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SNAKE BITES; SPIDERS;

ANIMALIA; ARANEAE; SCORPIONES;

EID: 77951665039     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.02.022     Document Type: Review

References (192)

1. Abroug F., Elatrous S., Nouira S., Haguiga H., Touzi N., Bouchoucha S. Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet 1999, 354:906-909.
2. Abroug F., Nouira S., Haguiga H., Elatrous S., Belghith M., Boujdaria R., Touzi N., Bouchoucha S. High-dose hydrocortisone hemisuccinate in scorpion envenomation. Ann. Emerg. Med. 1997, 30:23-27.
3. Abubakar S.B., Abubakar I.S., Habib A.G., Nasidi A., Durfa N., Yusuf P.O., Larnyang S., Garnvwa J., Sokomba E., Salako L., Laing G.D., Theakston R.D., Juszczak E., Alder N., Warrell D.A. Pre-clinical and preliminary dose-finding and safety studies to identify candidate antivenoms for treatment of envenoming by saw-scaled or carpet vipers (Echis ocellatus) in northern Nigeria. Toxicon 2010, 55:719-723. Nigeria-UK EchiTab Study Group.
4. Açikalin A., Gökel Y., Kuvandik G., Duru M., Köseoĝlu Z., Satar S. The efficacy of low-dose antivenom therapy on morbidity and mortality in snakebite cases. Am. J. Emerg. Med 2008, 26:402-407.
5. Agarwal R., Aggarwal A.N., Gupta D., Behera D., Jindal S.K. Low dose of snake antivenom is as effective as high dose in patients with severe neurotoxic snake envenoming. Emerg. Med J. 2005, 22:397-399.
6. Altman D.G. Better reporting of randomised controlled trials: the CONSORT statement. Br. Med. J. 1996, 313:570-571.
7. Altman D.G. Poor-quality medical research. What can journals do?. JAMA 2002, 287:2765-2767.
8. Altman D.G., Bland J.M. Absence of evidence is not evidence of absence?. Br. Med. J. 1995, 311:485.
9. Altman D.G., Bland J.M. Treatment allocation in controlled trials: why randomize?. Br. Med. J. 1999, 318:1209.
10. Altman D.G., Schulz K.F. Statiscal notes. Concealling treatment allocation in randomized trials. Br. Med. J. 2001, 323:446-447.
11. Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., Elbourne D., Gøtzsche P.C., Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 2001, 134:663-694. CONSORT GROUP (Consolidated Standards of Reporting Trials).
12. Amaral C.F., Campolina D., Dias M.B., Bueno C.M., Chávez-Olortegui C., Penaforte C.L., Diniz C.R., Rezende N.A. Time factor in the detection of circulating whole venom and crotoxin and efficacy of antivenom therapy in patients envenomed by Crotalus durissus. Toxicon 1997, 35:699-704.
13. Amaral C.F., Campolina D., Dias M.B., Bueno C.M., Rezende N.A. Tourniquet ineffectiveness to reduce the severity of envenoming after Crotalus durissus snake bite in Belo Horizonte, Minas Gerais, Brazil. Toxicon 1998, 36:805-808.
14. Ariaratnam C.A., Meyer W.P., Perera G., Eddleston M., Kuleratne S.A., Attapattu W., Sheriff R., Richards A.M., Theakston R.D., Warrell D.A. A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia russelii russelii): a preliminary dose-finding and pharmacokinetic study. Am. J. Trop. Med. Hyg. 1999, 61:259-265.
15. Ariaratnam C.A., Sjöström L., Raziek Z., Kularatne S.A., Arachchi R.W., Sheriff M.H., Theakston R.D., Warrell D.A. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii). Trans. R. Soc. Trop. Med. Hyg. 2001, 95:74-80.
16. Armitage P. Attitudes in clinical trials. Stat. Med. 1998, 17:2675-2683.
17. Atkinson P.R., Boyle A., Hartin D., McAuley D. Is hot water immersion an effective treatment for marine envenomation?. Emerg. Med. J. 2006, 23:503-508.
18. Bawaskar H.S., Bawaskar P.H. Role of atropine in management of cardiovascular manifestations of scorpion envenoming in humans. J. Trop. Med. Hyg. 1992, 95:30-35.
19. Bawaskar H.S., Bawaskar P.H. Prazosin therapy and scorpion envenomation. J. Assoc. Physicians India 2000, 48:1175-1180.
20. Bawaskar H.S., Bawaskar P.H. Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. J. Assoc. Physicians India 2007, 55:14-21.
21. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K.F., Simel D., Stroup D.F. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 276:637-639.
22. Belghith M., Boussarsar M., Haguiga H., Besbes L., Elatrous S., Touzi N., Boujdaria R., Bchir A., Nouira S., Bouchoucha S., Abroug F. Efficacy of serotherapy in scorpion sting: a matched-pair study. J. Toxicol. Clin. Toxicol. 1999, 37:51-57.
23. Bentur Y., Raikhlin-Eisenkraft B., Galperin M. Evaluation of antivenom therapy in Vipera palaestinae bites. Toxicon 2004, 44:53-57.
24. Bentur Y., Zveibel F., Adler M., Raikhlin B. Delayed administration of Vipera xanthina palaestinae antivenin. J. Toxicol. Clin. Toxicol. 1997, 35:257-261.
25. Berger V.W., Bears J.D. When can a clinical trial be called 'randomized'?. Vaccine 2003, 21:468-472.
26. Biswal N., Bashir R.A., Murmu U.C., Mathai B., Balachander J., Srinivasan S. Outcome of scorpion sting envenomation after a protocol guided therapy. Indian J. Pediatr. 2006, 73:577-582.
27. Bregant E.R., Cantoni F., Tantardini F. Snake bites in South Chad. Comparison between three different polyvalent anti-snake venom immunotherapies. Giorn. Ital. Med. Trop. 2006, 11:25-28.
28. Brian M.J., Vince J.D. Treatment and outcome of venomous snake bite in children Port Moresby General Hospital, Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 1987, 81:850-852.
29. Brown S.G., Wiese M.D., Blackman K.E., Heddle R.J. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003, 361:1001-1006.
30. Bouaziz M., Bahloul M., Kallel H., Samet M., Ksibi H., Dammak H., Ahmed M.N., Chtara K., Chelly H., Hamida C.B., Rekik N. Epidemiological, clinical characteristics and outcome of severe scorpion envenomation in South Tunisia: multivariate analysis of 951 cases. Toxicon 2008, 52:918-926.
31. Boyer L.V., Theodorou A.A., Berg R.A., Mallie J., Chávez-Méndez A., García-Ubbelohde W., Hardiman S., Alagón A. Antivenom for critically ill children with neurotoxicity from scorpion stings. N. Engl. J. Med. 2009, 360:2090-2098. Arizona Envenomation Investigators.
32. Bucaretchi F., Douglas J.L., Fonseca M.R., Zambrone F.A., Vieira R.J. Envenenamento ofídico em crianças: frequência de reações precoces ao antiveneno em pacientes que receberam pré-tratamento com antagonistas H1 e H2 da histamina e hidrocortisona. Rev. Inst. Med. Trop. Sao Paulo 1994, 36:451-457.
33. Bucher B., Canonge D., Thomas L., Tyburn B., Robbe-Vincent A., Choumet V., Bon C., Ketterlé J., Lang J. Clinical indicators of envenoming and serum levels of venom antigens in patients bitten by Bothrops lanceolatus in Martinique. Trans. R. Soc. Trop. Med. Hyg. 1997, 91:186-190. Research Group on Snake Bites in Martinique.
34. Bush S.P., Green S.M., Moynihan J.A., Hayes W.K., Cardwell M.D. Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). Ann. Emerg. Med. 2002, 40:619-624.
35. Caiaffa W.T., Vlahov D., Antunes C.M., de Oliveira H.R., Diniz C.R. Snake bite and antivenom complications in Belo Horizonte, Brazil. Trans. R. Soc. Trop. Med. Hyg. 1994, 88:81-85.
36. Cannon R., Ruha A.M., Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann. Emerg. Med. 2008, 51:407-411.
37. Caovilla J.J., Guardão Barros E.J. Efficacy of two different doses of antilonomic serum in the resolution of hemorrhagic syndrome resulting from envenoming by Lonomia obliqua caterpillars: a randomized controlled trial. Toxicon 2004, 43:811-818.
38. Cardoso J.L., Fan H.W., França F.O., Jorge M.T., Leite R.P., Nishioka S.A., Avila A., Sano-Martins I.S., Tomy S.C., Santoro M.L., Chudzinski A.M., Castro A.S., Kamiguti A.S., Kelen E.M.A., Hirata M.H., Mirandola R.M.S., Theakston R.D.G., Warrell D.A. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Q. J. Med. 1993, 86:315-325.
39. Caron E.J., Manock S.R., Maudlin J., Koleski J., Theakston R.D., Warrell D.A., Smalligan R.D. Apparent marked reduction in early antivenom reactions compared to historical controls: was it prophylaxis gold method off administration?. Toxicon 2009, Jun 9. (Epub ahead off print).
40. Casagrande J.T., Pike M.C., Smith P.G. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978, 34:483-486.
41. Chen J.C., Bullard M.J., Chiu T.F., Ng C.J., Liaw S.J. Risk of immediate effects from F(ab)2 bivalent antivenin in Taiwan. Wilderness Environ. Med. 2000, 11:163-167.
42. Chippaux J.P. Snake-bites: appraisal of the global situation. Bull. World Health Org. 1998, 76:515-524.
43. Chippaux J.P. The development and use of immunotherapy in Africa. Toxicon 1998, 36:1503-1506.
44. Chippaux J.P. The treatment of snake bites: analysis of requirements and assessment of therapeutic efficacy in tropical Africa. Perspectives in Molecular Toxicology 2002, 457-472. John Wiley & Sons, Ltd, Australia. A. Ménez (Ed.).
45. Chippaux J.P. Pratique des essais cliniques en Afrique 2006, IRD, Paris.
46. Chippaux J.P. Estimating the global burden of snakebite can help to improve management. PLoS Med. 2008, 5:e221.
47. Chippaux J.P., Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 1998, 36:823-846.
48. Chippaux J.P., Goyffon M. Epidemiology of scorpionism: a global appraisal. Acta Trop. 2008, 107:71-79.
49. Chippaux J.P., Lang J., Amadi-Eddine S., Fagot P., Le Mener V. Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. Am. J. Trop. Med. Hyg. 1999, 61:1017-1018.
50. Chippaux J.P., Lang J., Eddine S.A., Fagot P., Rage V., Peyrieux J.C., Le Mener V. Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:657-662. VAO (Venin Afrique de l'Ouest) Investigators.
51. 2 polyvalent equine antivenom for African snake bites in Benin. Am. J. Trop. Med. Hyg. 2007, 77:538-546. Invest. African Antivipmyn in Benin.
52. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Mahwah, NJ. second ed.
53. Concato J., Horwitz R.I. Beyond randomised versus observational studies. Lancet 2004, 363:1660-1661.
54. Corneille M.G., Larson S., Stewart R.M., Dent D., Myers J.G., Lopez P.P., McFarland M.J., Cohn S.M. A large single-center experience with treatment of patients with crotalid envenomations: outcomes with and evolution of antivenin therapy. Am. J. Surg. 2006, 192:848-852.
55. D'Agostino R.B., Massaro J.M., Sullivan L.M. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statist. Med. 2003, 22:169-186.
56. Dart R.C., Seifert S.A., Boyer L.V., Clark R.F., Hall E., McKinney P., McNally J., Kitchens C.S., Curry S.C., Bogdan G.M., Ward S.B., Porter R.S. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch. Intern. Med. 2001, 161:2030-2036.
57. Dart R.C., Seifert S.A., Carroll L., Clark R.F., Hall E., Boyer-Hassen L.V., Curry S.C., Kitchens C.S., Garcia R.A. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann. Emerg. Med. 1997, 30:33-39.
58. Dassanayake A.S., Karunanayake P., Kasturiratne K.T., Fonseka M.M., Wijesiriwardena B., Gunatilake S.B., de Silva H.J. Safety of subcutaneous adrenaline as prophylaxis against acute adverse reactions to anti-venom serum in snakebite. Ceylon Med. J. 2002, 47:48-49.
59. Daudu I., Theakston R.D. Preliminary trial of a new polyspecific antivenom in Nigeria. Ann. Trop. Med. Parasitol. 1988, 82:311-313.
60. El Hafny B., Ghalim N. Evolution clinique et taux circulants du venin dans les envenimations scorpioniques au Maroc. Bull. Soc. Pathol. Exot. 2002, 95:200-204.
61. Ellis R.M., Sprivulis P.C., Jelinek G.A., Banham N.D., Wood S.V., Wilkes G.J., Siegmund A., Roberts B.L. A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenoming. Emerg. Med. Australas 2005, 17:152-156.
62. Fan H.W., Marcopito L.F., Cardoso J.L., França F.O., Malaque C.M., Ferrari R.A., Theakston R.D., Warrell D.A. Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for Bothrops snake bites. Br. Med. J. 1999, 318:1451-1452.
63. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Meth. 2007, 39:175-191.
64. Fisher L.D. Advances in clinical trials in the twentieth century. Annu. Rev. Public Health 1999, 20:109-124.
65. Gateau T., Bloom M., Clark R. Response to specific Centruroides sculpturatus antivenom in 151 cases of scorpion stings. J. Toxicol. Clin. Toxicol. 1994, 32:165-171.
66. Gawarammana I.B., Kularatne S.A., Dissanayake W.P., Kumarasiri R.P., Senanayake N., Ariyasena H. Parallel infusion of hydrocortisone+/-chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med. J. Aust. 2004, 180:20-23.
67. Gibly R., Williams M., Walter F.G., McNally J., Conroy C., Berg R.A. Continuous intravenous midazolam infusion for Centruroides exilicauda scorpion envenomation. Ann. Emerg. Med. 1999, 34:620-625.
68. Ghalim N., El-Hafny B., Sebti F., Heikel J., Lazar N., Moustanir R., Benslimane A. Scorpion envenomation and serotherapy in Morocco. Am. J. Trop. Med. Hyg. 2000, 62:277-283.
69. Ghosh S., Maisnam I., Murmu B.K., Mitra P.K., Roy A., Simpson I.D. A locally developed snakebite management protocol significantly reduces overall anti snake venom utilization in West Bengal, India. Wilderness Environ. Med. 2008, 19:267-274.
70. Goodman S.N., Berlin J.A. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann. Intern. Med. 1 Aug 1994, 121(3):200-206.
71. Grasset E. Survey of assay methods of antivenins; immunological factors influencing antivenin standardization. Bull. World Health Org. 1957, 16:79-122.
72. Gutiérrez J.M., Theakston R.D., Warrell D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med. 2006, 3(6):e150.
73. Gutiérrez J.M., Williams D., Fan H.W., Warrell D.A. Snakebite envenoming from a global perspective: towards an integrated approach. Toxicon 2010, [Epub ahead of print].
74. Hammoudi-Triki D., Ferquel E., Robbe-Vincent A., Bon C., Choumet V., Laraba-Djebari F. Epidemiological data, clinical admission gradation and biological quantification by ELISA of scorpion envenomations in Algeria: effect of immunotherapy. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:240-250.
75. Hanvivatvong O., Mahasandana S., Karnchanachetanee C. Kinetic study of Russell's viper venom in envenomed patients. Am. J. Trop. Med. Hyg. 1997, 57:605-609.
76. ®, nouvel antivenin par voie veineuse. Ann. Fr. Anesth. Reanim. 1998, 17:681-687.
77. Harrington D.P. The randomized clinical trial. J. Am. Stat. Assoc. 2000, 95:312-315.
78. 2 purifiés (Viperfav™) par voie veineuse. Presse Med. 1999, 28:1929-1934.
79. Hile D.C., Coon T.P., Skinner C.G., Hile L.M., Levy P., Patel M.M., Miller M.A. Treatment of imported fire ant stings with mitigator sting and bite treatment - a randomized control study. Wilderness Environ. Med. 2006, 17:21-25.
80. Ho M., Silamut K., White N.J., Karbwang J., Looareesuwan S., Phillips R.E., Warrell D.A. Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am. J. Trop. Med. Hyg. 1990, 42:260-266.
81. Hopewell S., Clarke M., Moher D., Wager E., Middleton P., Altman D.G., Schulz K.F. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008, 5:e20. CONSORT Group.
82. Huang T.T., Blackwell S.J., Lewis S.R. Hand deformities in patients with snakebite. Plast. Reconstr. Surg. 1978, 62:32-36.
83. Hung D.Z., Liau M.Y., Lin-Shiau S.Y. The clinical significance of venom detection in patients of cobra snakebite. Toxicon 2003, 41:409-415.
84. Hung D.Z., Yu Y.J., Hsu C.L., Lin T.J. Antivenom treatment and renal dysfunction in Russell's viper snakebite in Taiwan: a case series. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:489-494.
85. Isbister G.K. Snake antivenom research: the importance of case definition. Emerg. Med. J. 2005, 22:399-400.
86. Isbister G.K. Clinical trials in toxinology: more than a discussion between friends?. Emerg. Med. Australas 2006, 18:4-6.
87. Isbister G.K. Safety of i.v. administration of redback spider antivenom. Intern. Med. J. 2007, 37:820-822.
88. Isbister G.K., Brown S.G., MacDonald E., White J., Currie B.J. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. Med. J. Aust. 2008, 188:473-476. Australian Snakebite Project Investigators.
89. Isbister G.K., Brown S.G., Miller M., Tankel A., Macdonald E., Stokes B., Ellis R., Nagree Y., Wilkes G.J., James R., Short A., Holdgate A. A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism-the RAVE study. Q. J. Med. 2008, 101:557-565.
90. Isbister G.K., Gray M.R. Latrodectism: a prospective cohort study of bites by formally identified redback spiders. Med. J. Aust. 2003, 179:88-91.
91. Isbister G.K., O'Leary M., Miller M., Brown S.G., Ramasamy S., James R., Schneider J.S. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. Br. J. Clin. Pharmacol. 2008, 65:139-143.
92. Isbister G.K., O'Leary M.A., Schneider J.J., Brown S.G., Currie B.J., Invest A.S.P. Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. Toxicon 2007, 49:57-67.
93. Jones B., Jarvis P., Lewis J.A., Ebbutt A.F. Trials to assess equivalence: the importance of rigorous methods. Br. Med. J. 1996, 313:36-39.
94. Jorge M.T., Cardoso J.L., Castro S.C., Ribeiro L., França F.O., de Almeida M.E., Kamiguti A.S., Santo-Martins I.S., Santoro M.L., Mancau J.E., Warrell D.A., Theakston R.D. A randomized 'blinded' comparison of two doses of antivenom in the treatment of Bothrops envenoming in São Paulo, Brazil. Trans. R. Soc. Trop. Med. Hyg. 1995, 89:111-114.
95. Jorge M.T., Malaque C., Ribeiro L.A., Fan H.W., Cardoso J.L., Nishioka S.A., Sano-Martins I.S., França F.O., Kamiguti A.S., Theakston R.D., Warrell D.A. Failure of chloramphenicol prophylaxis to reduce the frequency of abscess formation as a complication of envenoming by Bothrops snakes in Brazil: a double-blind randomized controlled trial. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:529-534.
96. Jorge M.T., Ribeiro L.A. Efeito na redução dose de soro antibotrópico administrada a pacientes picados por serpentes do gênero Bothrops. Rev. Assoc. Med. Bras. 1994, 40:59-62.
97. Karlson-Stiber C., Persson H. Antivenom treatment in Vipera berus envenoming-report of 30 cases. J. Intern. Med. 1994, 235:57-61.
98. Karlson-Stiber C., Persson H., Heath A., Smith D., Al-Abdulla I.H., Sjöström L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J. Intern. Med. 1997, 241:53-58.
99. Karnchanachetanee C., Hanvivatvong O., Mahasandana S. Monospecific antivenin therapy in Russell's viper bite. J. Med. Assoc. Thai. 1994, 77:293-297.
100. Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G., de Silva H.J. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008, 5:e218.
101. Kerrigan K.R., Mertz B.L., Nelson S.J., Dye J.D. Antibiotic prophylaxis for pit viper envenomation: prospective, controlled trial. World J. Surg. 1997, 21:369-372.
102. Kimoto T., Suemitsu K., Nakayama H., Komori E., Ohtani M., Ando S. Therapeutic experience of venomous snakebites by the Japanese viper (Agkistrodon halys Blomhoffii) with low dose of antivenin: report of 43 consecutive cases. Nippon Geka Hokan [Archiv für japanische Chirurgie] 1997, 66:71-77.
103. Krifi M.N., Amri F., Kharrat H., El Ayeb M. Evaluation of antivenom therapy in children severely envenomed by Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot) scorpions. Toxicon 1999, 37:1627-1634.
104. Krishnan A., Sonawane R.V., Karnad D.R. Captopril in the treatment of cardiovascular manifestations of indian red scorpion (Mesobuthus tamulus concanesis Pocock) envenomation. J. Assoc. Physicians India 2007, 55:22-26.
105. Kularatne S.A., Gawarammana I.B., Kumarasiri P.V., Senanayake N., Dissanayake W.P., Ariyasena H. Safety and efficacy of subcutaneous adrenaline as a treatment for anaphylactic reactions to polyvalent antivenom. Ceylon Med. J. 2003, 48:148-149.
106. Kularatne S.A., Kumarasiri P.V., Pushpakumara S.K., Dissanayaka W.P., Ariyasena H., Gawarammana I.B., Senanayake N. Routine antibiotic therapy in the management of the local inflammatory swelling in venomous snakebites: results of a placebo-controlled study. Ceylon Med. J. 2005, 50:151-155.
107. Lalloo D.G., Trevett A.J., Black J., Mapao J., Saweri A., Naraqi S., Owens D., Kamiguti A.S., Hutton R.A., Theakston R.D., Warrell D.A. Neurotoxicity, anticoagulant activity and evidence of rhabdomyolysis in patients bitten by death adders (Acanthophis sp.) in southern Papua New Guinea. Q. J. Med. 1996, 89:25-35.
108. Lalloo D.G., Trevett A.J., Korinhona A., Nwokolo N., Laurenson I.F., Paul M., Black J., Naraqi S., Mavo B., Saweri A., Hutton R.A., Theakston R.D.G., Warrell D.A. Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom. Am. J. Trop. Med. Hyg. 1995, 52:525-531.
109. Lavonas E.J., Gerardo C.J., O'Malley G., Arnold T.C., Bush S.P., Banner W., Steffens M., Kerns W.P. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. Ann. Emerg. Med. 2004, 43:200-206.
110. LoVecchio F., DeBus D.M. Snakebite envenomation in children: a 10-year retrospective review. Wilderness Environ. Med. 2001, 12:184-189.
111. LoVecchio F., Klemens J., Roundy E.B., Klemens A. Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ. Med. 2003, 14:220-221.
112. LoVecchio F., Welch S., Klemens J., Curry S.C., Thomas R. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann. Emerg. Med. 1999, 34:615-619.
113. Machin D., Campbell M., Fayers P., Pinol A. Sample Size Tables for Clinical Studies 1997, 24-25. Blackwell Science, Oxford. second ed.
114. Maclure M. Explaining pragmatic trials to pragmatic policymakers. J. Clin. Epidemiol. 2009, 62:476-478.
115. MacMahon S., Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001, 357:455-462.
116. Macpherson H. Pragmatic clinical trials. Complement Ther. Med. 2004, 12:136-140.
117. Malasit P., Warrell D.A., Chanthavanich P., Viravan C., Mongkolsapaya J., Singhthong B., Supich C. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br. Med. J. 1986, 292:17-20.
118. Mann G. Echis colorata bites in Israel: an evaluation of specific antiserum use on the base of 21 cases of snake bite. Toxicol. Eur. Res. 1978, 1:365-369.
119. Meyer W.P., Habib A.G., Onayade A.A., Yakubu A., Smith D.C., Nasidi A., Daudu I.J., Warrell D.A., Theakston R.D. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Am. J. Trop. Med. Hyg. 1997, 56:291-300.
120. Mille R., Saint-Cyr C., Petit P. La sérothérapie spécifique des envenomations par « Bothrops lanceolatus ». Premier essai thérapeutique d'un sérum monovalent préparé par l'Institut Pasteur. Bord. Med. 1970, 3:1023-1030.
121. Mitrakul C., Dhamkrong-At A., Futrakul P., Thisyakorn C., Vongsrisart K., Varavithya C., Phancharoen S. Clinical features of neurotoxic snake bite and response to antivenom in 47 children. Am. J. Trop. Med. Hyg. 1984, 33:1258-1266.
122. Moran N.F., Newman W.J., Theakston R.D., Warrell D.A., Wilkinson D. High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:69-70.
123. Myint-Lwin Tin-Nu-Swe, Myint-Aye-Mu Than-Than, Thein-Than Tun-Pe. Heparin therapy in Russell's viper bite victims with impending dic (a controlled trial). Southeast Asian J. Trop. Med. Public Health 1989, 20:271-277.
124. Myint-Lwin D.A., Phillips R.E., Tin-Nu-Swe, Tun-Pe, Maung-Maung-Lay, Warrell Bites by Russell's viper (Vipera russelli siamensis) in Burma: haemostatic, vascular, and renal disturbances and response to treatment. Lancet 1985, 2:1259-1264.
125. Narvencar K. Correlation between timing of ASV administration and complications in snake bites. J. Assoc. Physicians India 2006, 54:717-719.
126. Natu V.S., Murthy R.K., Deodhar K.P. Efficacy of species specific anti-scorpion venom serum (AScVS) against severe, serious scorpion stings (Mesobuthus tamulus concanesis Pocock) - an experience from rural hospital in western Maharashtra. J. Assoc. Physicians India 2006, 54:283-287.
127. Nuchprayoon I., Pongpan C., Sripaiboonkij N. The role of prednisolone in reducing limb oedema in children bitten by green pit vipers: a randomized, controlled trial. Ann. Trop. Med. Parasitol. 2008, 102:643-649.
128. Offerman S.R., Bush S.P., Moynihan J.A., Clark R.F. Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. Pediatrics 2002, 110:968-971.
129. Offerman S.R., Smith T.S., Derlet R.W. Does the aggressive use of polyvalent antivenin for rattlesnake bites result in serious acute side effects?. West. J. Med. 2001, 175:88-91.
130. Otero R., Gutiérrez J.M., Núñez V., Robles A., Estrada R., Segura E., Toro M.F., García M.E., Díaz A., Ramírez E.C., Gómez G., Castañeda J., Moreno M.E. A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Trans. R. Soc. Trop. Med. Hyg. 1996, 90:696-700.
131. Otero R., Gutiérrez J.M., Rojas G., Núñez V., Díaz A., Miranda E., Uribe A.F., Silva J.F., Ospina J.G., Medina Y., Toro M.F., García M.E., León G., García M., Lizano S., De La Torre J., Márquez J., Mena Y., González N., Arenas L.C., Puzón A., Blanco N., Sierra A., Espinal M.E., Arboleda M., Jiménez J.C., Ramírez P., Díaz M., Guzmán M.C., Barros J., Henao S., Ramírez A., Macea U., Lozano R. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 1999, 37:895-908.
132. Otero R., León G., Gutiérrez J.M., Rojas G., Toro M.F., Barona J., Rodríguez V., Díaz A., Núñez V., Quintana J.C., Ayala S., Mosquera D., Conrado L.L., Fernández D., Arroyo Y., Paniagua C.A., López M., Ospina C.E., Alzate C., Fernández J., Meza J.J., Silva J.F., Ramírez P., Fabra P.E., Ramírez E., Córdoba E., Arrieta A.B., Warrell D.A., Theakston R.D. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:1173-1182.
133. Otero-Patiño R., Cardoso J.L., Higashi H.G., Nunez V., Diaz A., Toro M.F., García M.E., Sierra A., García L.F., Moreno A.M., Medina M.C., Castañeda N., Silva-Diaz J.F., Murcia M., Cardenas S.Y., Dias da Silva W.D. A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Uraba, Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Am. J. Trop. Med. Hyg. 1998, 58:183-189.
134. Pardal P.P., Souza S.M., Monteiro M.R., Fan H.W., Cardoso J.L., França F.O., Tomy S.C., Sano-Martins I.S., de Sousa-e-Silva M.C., Colombini M., Kodera N.F., Moura-da-Silva A.M., Cardoso D.F., Velarde D.T., Kamiguti A.S., Theakston R.D., Warrell D.A. Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:28-42.
135. Paul V., Prahlad K.A., Earali J., Francis S., Lewis F. Trial of heparin in viper bites. J. Assoc. Physicians India 2003, 51:163-166.
136. Paul V., Pratibha S., Prahlad K.A., Earali J., Francis S., Lewis F. High-dose anti-snake venom versus low-dose anti-snake venom in the treatment of poisonous snake bites-a critical study. J. Assoc. Physicians India 2004, 52:14-17.
137. Paul V., Pudoor A., Earali J., John B., Anil Kumar C.S., Anthony T. Trial of low molecular weight heparin in the treatment of viper bites. J. Assoc. Physicians India 2007, 55:338-342.
138. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., Smith P.G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer 1976, 34:585-612.
139. Phillips R.E., Theakston R.D., Warrell D.A., Galigedara Y., Abeysekera D.T., Dissanayaka P., Hutton R.A., Aloysius D.J. Paralysis, rhabdomyolysis and haemolysis caused by bites of Russell's viper (Vipera russelli pulchella) in Sri Lanka: failure of Indian (Haffkine) antivenom. Q. J. Med. 1988, 68:691-715.
140. Pizon A.F., Riley B.D., LoVecchio F., Gill R. Safety and efficacy of Crotalidae Polyvalent Immune Fab in pediatric crotaline envenomations. Acad. Emerg. Med. 2007, 14:373-376.
141. Pochanugool C., Limthongkul S., Wilde H. Management of Thai cobra bites with a single bolus of antivenin. Wilderness Environ. Med. 1997, 8:20-23.
142. Premawardhena A.P., de Silva C.E., Fonseka M.M., Gunatilake S.B., de Silva H.J. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial. Br. Med. J. 1999, 318:1041-1043.
143. Reid H.A., Thean P.C., Martin W.J. Specific antivenene and prednisone in viper-bite poisoning: controlled trial. Br. Med. J. 1963, 2:1378-1380.
144. Rezende N.A., Dias M.B., Campolina D., Chavez-Olortegui C., Diniz C.R., Amaral C.F. Efficacy of antivenom therapy for neutralizing circulating venom antigens in patients stung by Tityus serrulatus scorpions. Am. J. Trop. Med. Hyg. 1995, 52:277-280.
145. Rojnuckarin P., Chanthawibun W., Noiphrom J., Pakmanee N., Intragumtornchai T. A randomized, double-blind, placebo-controlled trial of antivenom for local effects of green pit viper bites. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:879-884.
146. Ruha A.M., Curry S.C., Beuhler M., Katz K., Brooks D.E., Graeme K.A., Wallace K., Gerkin R., LoVecchio F., Wax P., Selden B. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann. Emerg. Med. 2002, 39:609-615.
147. Schulz K.F., Grimes D.A. Sample size calculations in randomised trials: mandatory and mystical. Lancet 2005, 365:1348-1353.
148. Schwartz D., Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 1967, 20:637-648. (Reprinted in 2009. J. Clin. Epidemiol. 62, 499-505).
149. Sellahewa K.H., Gunawardena G., Kumararatne M.P. Efficacy of antivenom in the treatment of severe local envenomation by the hump-nosed viper (Hypnale hypnale). Am. J. Trop. Med. Hyg. 1995, 53:260-262.
150. Sellahewa K.H., Kumararatne M.P., Dassanayake P.B., Wijesundera A. Intravenous immunoglobulin in the treatment of snake bite envenoming: a pilot study. Ceylon Med. J. 1994, 39:173-175.
151. Seneviratne S.L., Opanayaka C.J., Ratnayake N.S., Kumara K.E., Sugathadasa A.M., Weerasuriya N., Wickrama W.A., Gunatilake S.B., de Silva H.J. Use of antivenom serum in snake bite: a prospective study of hospital practice in the Gampaha district. Ceylon Med. J. 2000, 45:65-68.
152. Shemesh I.Y., Kristal C., Langerman L., Bourvin A. Preliminary evaluation of Vipera palaestinae snake bite treatment in accordance to the severity of the clinical syndrome. Toxicon 1998, 36:867-873.
153. Smalligan R., Cole J., Brito N., Laing G.D., Mertz B.L., Manock S., Maudlin J., Quist B., Holland G., Nelson S., Lalloo D.G., Rivadeneira G., Barragan M.E., Dolley D., Eddleston M., Warrell D.A., Theakston R.D. Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms. Br. Med. J. 2004, 329:1129-1135.
154. Sofer S., Shahak E., Gueron M. Scorpion envenomation and antivenom therapy. J. Pediatr. 1994, 124:973-978.
155. Sotelo N. Review of treatment and complications in 79 children with rattlesnake bite. Clin. Pediatr. 2008, 47:483-489.
156. Srimannarayana J., Dutta T.K., Sahai A., Badrinath S. Rational use of anti-snake venom (ASV): trial of various regimens in hemotoxic snake envenomation. J. Assoc. Physicians India 2004, 52:788-793.
157. Stahel E., Wellauer R., Freyvogel T.A. Vergiftungen durch einheimische Vipern (Vipera berus und Vipera aspis). Eine retrospektive Studie an 113 Patienten. Schweiz. Med. Wschr. 1985, 115:890-896.
158. Stock R.P., Massougbodji A., Alagón A., Chippaux J.P. Bringing antivenom to Sub-Saharan Africa. Nat. Biotechnol. 2007, 25:173-177.
159. Streiner D.L. Alternatives to placebo-controlled trials. Can. J. Neurol. Sci. 2007, 34:S37-S41.
160. Sutherland S.K., Lovering K.E. Antivenoms: use and adverse reactions over a 12-month period in Australia and Papua New Guinea. Med. J. Aust. 1979, 2:671-674.
161. Swinson C. Control of antivenom treatment in Echis carinatus (Carpet Viper) poisoning. Trans. R. Soc. Trop. Med. Hyg. 1976, 70:85-87.
162. Tariang D.D., Philip P.J., Alexander G., Macaden S., Jeyaseelan L., Peter J.V., Cherian A.M. Randomized controlled trial on the effective dose of anti-snake venom in cases of snake bite with systemic envenomation. J. Assoc. Physicians India 1999, 47:369-371.
163. Theakston R.D., Fan H.W., Warrell D.A., Da Silva W.D., Ward S.A., Higashi H.G. Use of enzyme immunoassays to compare the effect and assess the dosage regimens of three Brazilian Bothrops antivenoms. Am. J. Trop. Med. Hyg. 1992, 47:593-604. The Butantan Institute Antivenom Study Group (BIASG).
164. Theakston R.D., Phillips R.E., Warrell D.A., Galagedera Y., Abeysekera D.T., Dissanayaka P., de Silva A., Aloysius D.J. Envenoming by the common krait (Bungarus caeruleus) and Sri Lankan cobra (Naja naja naja): efficacy and complications of therapy with Haffkine antivenom. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:301-308.
165. Theakston R.D., Warrell D.A., Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003, 41:541-557.
166. Theakston R.D.G., Warrell D.A. Crisis in snake antivenom supply for Africa. Lancet 2000, 356:2104.
167. 2 antivenom for snakebites in Thailand. Acta Trop. 2008, 105:203-205.
168. Thomas L., Tyburn B., Bucher B., Pecout F., Ketterle J., Rieux D., Smadja D., Garnier D., Plumelle Y. Prevention of thromboses in human patients with Bothrops lanceolatus envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific antivenom. Am. J. Trop. Med. Hyg. 1995, 52:419-426. Research Group on Snake Bites in Martinique.
169. 2 antivenimeux (équin) spécifique administré par voie intraveineuse dans le traitement des morsures de serpent (Bothrops lanceolatus) en Martinique. Réan. Urg. 1998, 7:381-387. Research Group on Snake Bites in Martinique.
170. Thomas P.P., Jacob J. Randomised trial of antivenom in snake envenomation with prolonged clotting time. Br. Med. J. 1985, 291:177-178.
171. Thorpe K.E., Zwarenstein M., Oxman A.D., Treweek S., Furberg C.D., Altman D.G., Tunis S., Bergel E., Harvey I., Magid D.J., Chalkidou K. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J. Clin. Epidemiol. 2009, 62:464-475.
172. Tin Nu Swe Myint Lwin, Khin Ei Han, Tin Tun Tun P. Heparin therapy in Russell's viper bite victims with disseminated intravascular coagulation: a controlled trial. Southeast Asian J. Trop. Med. Public Health 1992, 23:282-287.
173. Trevett A.J., Lalloo D.G., Nwokolo N.C., Naraqi S., Kevau I.H., Theakston R.D., Warrell D.A. The efficacy of antivenom in the treatment of bites by the Papuan taipan (Oxyuranus scutellatus canni). Trans. R. Soc. Trop. Med. Hyg. 1995, 89:322-325.
174. Trevett A.J., Lalloo D.G., Nwokolo N.C., Naraqi S., Kevau I.H., Theakston R.D., Warrell D.A. Failure of 3,4-diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni. Trans. R. Soc. Trop. Med. Hyg. 1995, 89:444-446.
175. Vandenbroucke J.P. When are observational studies as credible as randomised trials?. Lancet 2004, 363:1728-1731.
176. Vandenbroucke J.P. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008, 5:e67.
177. Vijeth S.R., Dutta T.K., Shahapurkar J., Sahai A. Dose and frequency of anti-snake venom injection in treatment of Echis carinatus (saw-scaled viper) bite. J. Assoc. Physicians India 2000, 48:187-191.
178. Visser L.E., Kyei-Faried S., Belcher D.W. Protocol and monitoring to improve snake bite outcomes in rural Ghana. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:278-283.
179. Visser L.E., Kyei-Faried S., Belcher D.W., Geelhoed D.W., van Leeuwen J.S., van Roosmalen J. Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:445-450.
180. Warrell D.A. Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product - 'what's in a name?'. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:397-399.
181. Warrell D.A., Davidson N.M., Omerod L.D., Pope H.M., Watkins B.J., Greenwood B.M., Reid H.A. Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms. Br. Med. J. 1974, 4:437-440.
182. Warrell D.A., Looareesuwan S., Theakston R.D., Phillips R.E., Chanthavanich P., Viravan C., Supanaranond W., Karbwang J., Ho M., Hutton R.A., Vejcho S. Randomized comparative trial of three monospecific antivenoms for bites by the Malayan pit viper (Calloselasma rhodostoma) in southern Thailand: clinical and laboratory correlations. Am. J. Trop. Med. Hyg. 1986, 35:1235-1247.
183. Warrell D.A., Ormerod L.D., Davidson N.M. Bites by puff-adder (Bitis arietans) in Nigeria, and value of antivenom. Br. Med. J. 1975, 4:697-700.
184. Warrell D.A., Pope H.M., Prentice C.R. Disseminated intravascular coagulation caused by the carpet viper (Echis carinatus): trial of heparin. Br. J. Haematol. 1976, 33:335-342.
185. Warrell D.A., Warrell M.J., Edgar W., Prentice C.R., Mathison J., Mathison J. Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus). Br. Med. J. 1980, 280:607-609.
186. Watt G., Meade B.D., Theakston R.D., Padre L.P., Tuazon M.L., Calubaquib C., Santiago E., Ranoa C.P. Comparison of Tensilon and antivenom for the treatment of cobra-bite paralysis. Trans. R. Soc. Trop. Med. Hyg. 1989, 83:570-573.
187. Watt G., Theakston R.D., Hayes C.G., Yambao M.L., Sangalang R., Ranoa C.P., Alquizalas E., Warrell D.A. Positive response to edrophonium in patients with neurotoxic envenoming by cobras (Naja naja philippinensis). A placebo-controlled study. New Engl. J. Med. 1986, 315:1444-1448.
188. WHO Progress in the Characterization of Venoms and Standarization of Antivenoms 1981, WHO Offset Publication, Geneva.
189. WHO. Guidelines on Production, Control and Regulation of Snake Antivenom Immunoglobulins. WHO, Geneva, in press.
190. Williams D.J., Jensen S.D., Nimorakiotakis B., Müller R., Winkel K.D. Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea. Toxicon 2007, 49:780-792.
191. Win-Aung Tin-Tun, Khin-Maung-Maung Aye-Kyaw, Hla-Pe Tin-Nu-Swe, Saw-Naing Clinical trial of intramuscular anti-snake venom administration as a first aid measure in the field in the management of Russell's viper bite patients. Southeast Asian J. Trop. Med. Public Health 1996, 27:494-497.
192. Yeung J.M., Little M., Murray L.M., Jelinek G.A., Daly F.F. Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years. Med. J. Aust. 2004, 181:703-705.